Pivagabine
| |
| Names | |
|---|---|
| Preferred IUPAC name
4-(2,2-Dimethylpropanamido)butanoic acid | |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
| ECHA InfoCard | 100.067.287 |
| EC Number |
|
| KEGG | |
| MeSH | N-trimethylacetyl-4-aminobutyric+acid |
PubChemCID
|
|
| UNII | |
CompTox Dashboard(EPA)
|
|
| |
| |
| Properties | |
| C9H17NO3 | |
| Molar mass | 187.239g·mol−1 |
| Pharmacology | |
| N06AX15(WHO) | |
| Oral | |
| Pharmacokinetics: | |
| 6.4 hours | |
| Legal status |
|
| Related compounds | |
Related alkanoic acids
|
|
Except where otherwise noted, data are given for materials in theirstandard state(at 25 °C [77 °F], 100 kPa).
| |
Pivagabine(INN;brand nameTonerg), also known asN-pivaloyl-γ-aminobutyric acidorN-pivaloyl-GABA,is anantidepressantandanxiolyticdrugwhich was introduced inItalyin 1997 for the treatment ofdepressiveandmaladaptivesyndromes.But it was discontinued in Italy (according toMartindale). Originally believed to function as aprodrugtoGABA,[1]pivagabine is now believed to act somehow via modulation ofcorticotropin-releasing factor(CRF).[2][3][4][5][6]
See also
[edit]References
[edit]- ^Bianchi M, Quadro G, Mourier G, Galzigna L (1983). "Pharmacokinetics and in vitro effects of a 4-aminobutyric acid derivative with anticonvulsant action".Pharmacology.27(4): 237–40.doi:10.1159/000137876.PMID6634934.
- ^Scapagnini U, Matera M (November 1997). "Effects of pivagabine on psychophysical performance and behavioural response in experimental models of stress".Arzneimittel-Forschung.47(11A): 1310–4.PMID9450154.
- ^Esposito G, Luparini MR (November 1997). "Pivagabine: a novel psychoactive drug".Arzneimittelforschung.47(11A): 1306–9.PMID9450153.
- ^Gerra G, Zaimovic A, Giusti F, et al. (July 2001). "Pivagabine effects on neuroendocrine responses to experimentally-induced psychological stress in humans".Behavioural Brain Research.122(1): 93–101.doi:10.1016/S0166-4328(01)00177-2.PMID11287080.S2CID23067609.
- ^Serra M, Concas A, Mostallino MC, et al. (April 1999). "Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotropin-releasing factor concentrations in rat brain".Psychoneuroendocrinology.24(3): 269–84.doi:10.1016/S0306-4530(98)00049-3.PMID10101733.S2CID11382166.
- ^George I. Papakostas; Maurizio Fava (2010).Pharmacotherapy for Depression and Treatment-resistant Depression.World Scientific. pp. 370–.ISBN978-981-4287-59-3.